EBNA-1 Antikörper (AA 551-641) (Cy7)
-
- Target Alle EBNA-1 Antikörper anzeigen
- EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))
- Bindungsspezifität
- AA 551-641
- Reaktivität
- Epstein-Barr Virus (EBV), Virus
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser EBNA-1 Antikörper ist konjugiert mit Cy7
-
Applikation
- Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- Kreuzreaktivität
- Virus
- Kreuzreaktivität (Details)
- Epstein Barr Virus
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from EBV Nuclear Antigen
- Isotyp
- IgG
- Top Product
- Discover our top product EBNA-1 Primärantikörper
-
-
- Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Haltbarkeit
- 12 months
-
- Target
- EBNA-1 (Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1))
- Andere Bezeichnung
- EBV Nuclear Antigen (EBNA-1 Produkte)
- Synonyme
- EBNA-1 antikoerper, latency protein antikoerper, CeHV15gEBNA-1 antikoerper, EBNA-1 antikoerper, HHV4tp2_gp36 antikoerper
- Substanzklasse
- Viral Protein
- Hintergrund
-
Synonyms: EBNA1, EBNA-1, EBV nuclear antigen 1, Epstein Barr nuclear antigen 1, Epstein Barr virus, BKRF1, Epstein-Barr nuclear antigen 1, EBV nuclear antigen 1,
Background: Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.
-